Regular Article
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas

https://doi.org/10.1054/jocn.2000.0809Get rights and content

Abstract

Temozolomide has an evolving role in the treatment of high grade gliomas. Recent studies suggest that temozolomide is well tolerated and efficacious. This study retrospectively analysed the activity and toxicity associated with temozolomide at two Austr alian centres over a 24 month period. Fifty-six patients with recurrent high grade gliomas were treated with temozolomide. Patients received temozolomide orally at 150–200mg/m2daily, days 1–5, every 4 weeks. The median number of treatment cycles was 4 (1–12). Of the 56 patients, 15 (27%) achieved complete or partial response and 18 (32%) achieved minor response or stable disease. There were no episodes of febrile neutropenia and temozolomide was generally well tolerated. In conclusion, temozolomide is an active therapy in patients with recurrent high grade glioma and our results concord with published studies.

References (14)

  • SM O'Reilly et al.

    Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours

    Eur J Cancer

    (1993)
  • American Cancer Society, SEER statistics,...
  • Canstat 1994

    (1997)
  • E Burton et al.

    New chemotherapy options for the treatment of malignant gliomas

    Curr Opin Oncol

    (1999)
  • VA Levin

    Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading

    Neuro-Oncology

    (1999)
  • ET Wong et al.

    Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

    J Clin Oncol

    (1999)
  • E Newlands et al.

    Phase 1 trial of temozolomide

    Br J Cancer

    (1992)
There are more references available in the full text version of this article.

Cited by (0)

f1

Correspondence to: Mark Rosenthal, Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, 3052 Australia. Tel.: 61 3 9342 7560; Fax: 61 3 9347 7508; E-mail:[email protected]

View full text